Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms, Nerve Tissue 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × contrast agent BR1 × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡